Leap Therapeutics

LEAP THERAPEUTICS INC

Leap Therapeutics Inc is a biopharmaceutical company developing novel biomarker-targeted antibody therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways, targeting cancer-specific cell surface molecules, and harnessing the immune system to attack cancer cells. The company's key clinical-stage drug candidate is sirexatamab (DKN-01), which targets Dickkopf-related protein 1 (DKK1) and is being studied in a clinical trial in patients with colorectal cancer. In addition, it also has a preclinical program to develop a proprietary monoclonal antibody, called FL-501 which works by inhibiting the GDF-15 protein.

LPTX

Biotech

News

Health Care

Movers

Trading Ideas

General

Leap Therapeutics&#39; Phase 2 trial data show sirexatamab boosts response rates and survival in MSS colorectal cancer, with ongoing business development plans.

Penny Stock Leap Therapeutics Unveils Positive Data From Experimental Combo Therapy For Colorectal Cancer

iPad's Impact On Apple

Downgrades

Pre-Market Outlook

Markets

Analyst Ratings

AAPL

DDOG

MRNA

TCBX

This Apple Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday

Leap Therapeutics&#39; Phase 2 data shows sirexatamab improves ORR in colorectal cancer. Gastric cancer studies end due to lack of PFS benefit.

Leap Therapeutics Halts Sirexatamab Combo Therapy For Gastric Cancer ON Unclear Positive Signal, Stock Crashes

Leap Therapeutics Inc

Press Releases

Leap Therapeutics Announces Completion of Enrollment in Part B of the DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer Patients

Earnings

Leap Therapeutics Reports Third Quarter 2024 Financial Results

Leap Therapeutics to Participate at Piper Sandler 36th Annual Healthcare Conference

Leap Therapeutics to Participate at the 43rd Annual J.P. Morgan Healthcare Conference

Leap Therapeutics Reports Initial Clinical Data from Part B of the DeFianCe Study and Part C of the DisTinGuish Study

Leap Therapeutics Reports Positive Updated Data from Sirexatamab Colorectal Cancer Study

Leap Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

Driving the Future of Healthcare HIT, OSRH, THTX, LPTX, CSDX, Innovations in Health Insurance, Virtual Care, Oncology, and Chronic Disease Treatment

Leap Therapeutics to Host Virtual KOL Event to Discuss Sirexatamab (DKN-01) in Second-line Patients with Advanced Microsatellite Stable Colorectal Cancer

Leap Therapeutics to Present Preclinical Data of FL-501, a Novel GDF-15 Neutralizing Antibody, at the AACR 2025 Annual Meeting

CSDX

OSRH

THTX

Allarity Therapeutics, Inc. - Common stock

Allarity Therapeutics

BioCardia

Bolt Biotherapeutics, Inc. - Common Stock

Bolt Biotherapeutics

BioRestorative Therapies, Inc. - Common Stock

BioRestorative Therapies

Can-Fite Biopharma Ltd Sponsored ADR (Israel)

Can Fite Biofarma

Calidi Biotherapeutics, Inc. Common Stock

Calidi Biotherapeutics

Equillium

Ernexa Therapeutics

GlycoMimetics

Geovax Labs

Imunon

IN8bio

Kairos Pharma

Kazia Therapeutics Limited - American Depositary Shares

Kazia Therapeutics

Moleculin Biotech

MEI Pharma

Marker Therapeutics

BiomX

Portage Biotech

Q32 Bio

Rallybio

SAB Biotherapeutics

Synlogic

Unity Biotechnology

X4 Pharmaceuticals

Rodman & Renshaw

Baird

Mizuho

Raymond James

Comments

Leap Therapeutics

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell